Reminder: Field Trip: Boston Biotech Bus Trip 2026

研报英文原文证据摘录

Reminder: Field Trip: Boston Biotech Bus Trip 2026

Meet the Analysts

Eliana Merle, CFA, joined Barclays in November 2025 as an

Equity Research Analyst to cover U.S. Small & Mid Cap

Biotechnology. She has over a decade of sell-side equity

research experience in the sector; most recently, Ellie

worked as a Senior Equity Research Analyst at UBS in

Biotechnology for five years. Prior to that, she also

covered Small & Mid Cap Biotechnology at Cantor

Fitzgerald and held positions at Credit Suisse and

Deutsche Bank in Biotechnology Equity Research. Ellie

graduated from Pomona College with a degree in

Economics.

View Analyst Page

Emily Field, CFA is a Director and Head of U.S.

Biopharmaceuticals equity research at Barclays. Joining

the bank’s London office in 2017, she previously served as

Head of the European Pharmaceuticals team, earning a #4

individual ranking in European Pharmaceuticals &

Biotechnology in the 2025 Extel survey. With more than

two decades experience across both buy-side and sell-side

roles, she has worked across multiple investing strategies

including risk arbitrage and equity long/short. Prior to

Barclays, Ms. Field held positions at UBS O’Connor and

Millennium Management. Originally hailing from Chicago,

Ms. Field holds a B.A. in Economics and History from Yale

University, graduating with distinction in both majors, and

is a CFA charterholder.

Etzer Darout, PhD, MBA, is a Managing Director and equity

research analyst covering the U.S. Small and Mid-Cap

Biotechnology sector, with over 10 years of sell-side

research experience. Before joining Barclays in June 2025,

Etzer spent three years at BMO Capital Markets as a

Managing Director and senior equity research analyst

covering the Biotechnology sector. Prior to his career on